Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL407954 | 0.98 | DRD2 (0.33) | DRD2ADRA1AACHEHSD11B1LMNA | |
| SCHEMBL10744875 | 0.96 | LMNA (0.34) | DRD2ADRA1AACHEHSD11B1LMNA | |
| SCHEMBL1816491 | 0.96 | LMNA (0.34) | DRD2ADRA1AACHEHSD11B1LMNA | |
| SCHEMBL20281987 | 0.94 | KMT2A (0.34) | DRD2ADRA1AACHEHSD11B1LMNA | |
| SCHEMBL20281783 | 0.94 | KMT2A (0.34) | DRD2ADRA1AACHEHSD11B1LMNA | |
| SCHEMBL11020218 | 0.85 | DRD2 (0.39) | DRD2ADRA1AACHEHSD11B1 | |
| SCHEMBL11020237 | 0.85 | DRD2 (0.39) | DRD2ADRA1AACHEHSD11B1 | |
| SCHEMBL20281861 | 0.84 | ACHE (0.32) | ACHE | |
| SCHEMBL6216411 | 0.83 | DRD2 (0.44) | DRD2ADRA1AACHEHSD11B1 | |
| SCHEMBL11245835 | 0.82 | KMT2A (0.41) | DRD2ADRA1AACHEHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. | 2025-07-17 | — | — | US | disclosed |
| WO-2025137640-A1 | AZASPIRO WRN INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| US-8580807-B2 | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-8580807-B2 | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
| WO-2010114957-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | SCHERING CORPORATION (US) | 2010-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250230168-A1 | AZASPIRO WRN INHIBITORS | WRN, RECQL, BLM | DRD2 4837/4885ADRA1A 4121/4885ACHE 4376/4885 |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | GPR119, GPR55, GPR4 | DRD2 91/4885ADRA1A 72/4885ACHE 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.